Symptom Self-Management for Lung Cancer
Trial Summary
What is the purpose of this trial?
The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.
Do I need to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.
What data supports the effectiveness of the treatment Symptom Self-Management for Lung Cancer?
Research shows that both nurse-assisted and automated telephone symptom management can significantly reduce symptom severity in cancer patients, including those with lung cancer. Additionally, proactive telephone counseling has been effective in promoting smoking cessation, which is beneficial for lung cancer patients.12345
Is Automated Telephone Symptom Management (ATSM) safe for use in humans?
The Automated Telephone Symptom Management (ATSM) system has been tested in cancer patients undergoing chemotherapy and was found to significantly reduce symptom severity without any reported safety issues. However, lung cancer patients with severe symptoms were more likely to withdraw from the ATSM intervention, suggesting it may be less effective in retaining these patients.13467
How is the treatment Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C) unique for lung cancer?
This treatment is unique because it combines automated telephone systems with interpersonal counseling to help lung cancer patients manage their symptoms, offering a more interactive and supportive approach compared to traditional methods. It allows real-time symptom reporting and management, which can be particularly beneficial for patients experiencing severe symptoms.34789
Research Team
Terry Badger, PhD
Principal Investigator
University of Arizona
Eligibility Criteria
This trial is for adults over 18 who have started treatment with immune checkpoint inhibitors (ICIs) for various cancers within the last 12 weeks. Participants must be able to communicate in English or Spanish, have access to a phone, and show mild psychological distress. Those already receiving regular behavioral counseling cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Automated Telephone Symptom Management (ATSM) or active control condition for 16 weeks, with weekly symptom monitoring and potential addition of Telephone Interpersonal Counseling (TIPC) for nonresponders
Follow-up
Participants are monitored for safety and effectiveness after treatment, with interviews conducted at week 17
Treatment Details
Interventions
- Active control comparator
- Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)
Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C) is already approved in United States for the following indications:
- Symptom management for patients on immune checkpoint inhibitors
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Arizona
Lead Sponsor
National Cancer Institute (NCI)
Collaborator